62 reports of this reaction
1.6% of all LIDOCAINE HCL reports
#9 most reported adverse reaction
DYSPNOEA is the #9 most commonly reported adverse reaction for LIDOCAINE HCL, manufactured by Chattem, Inc.. There are 62 FDA adverse event reports linking LIDOCAINE HCL to DYSPNOEA. This represents approximately 1.6% of all 3,987 adverse event reports for this drug.
LIDOCAINE HCL has an overall safety score of 72 out of 100. Patients taking LIDOCAINE HCL who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for LIDOCAINE HCL, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for LIDOCAINE HCL:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 62 FDA reports for LIDOCAINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.6% of all adverse event reports for LIDOCAINE HCL, making it a notable side effect.
If you experience dyspnoea while taking LIDOCAINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.